Hiperhomocisteinemia, un nuevo marcador de riesgo vascular: Territorios vasculares afectados, papel en la patogénesis de la arteriosclerosis y la trombosis y tratamiento

Medicina Clinica

Volumn 109, Issue 18, 1997, Pages 715-725

  Córdoba Porras, Alfonso ^a,b,c   Blanco Vaca, Francisco ^a   González Sastre, Francesc ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; METHIONINE; VITAMIN;

ADULT; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; FEMALE; HOMOCYSTINURIA; HUMAN; MALE; METABOLISM; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; PREGNANCY; REVIEW; THROMBOPHLEBITIS;

ADULT; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; FEMALE; HOMOCYSTEINE; HOMOCYSTINURIA; HUMANS; MALE; METHIONINE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PREGNANCY; THROMBOPHLEBITIS; VITAMINS;

EID: 0031583658     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyertiz RE et al. The natural history of homocystinuria due to cystathione β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
2. Mudd SH, Levy HL, Skovy F. Disorders fo transsulfuration. En: Scriver CR, Beadet AL, Sly WS, Valle D, editores. The metabolic molecular bases of inherited diseases. Nueva York: McGraw-Hill Inc., 1995; 1.279-1.327.
3. White HH, Rowland LP, Araki S. Homocystinuria. Arch Neurol 1965; 13: 455-470.
4. Dunn HG, Perry TL, Dolman CL. Homocystinuria. Neurology 1996; 16: 407-419.
5. Carey MC, Donovan DE, Fitzgerald O, McAuley FD. Homocystinuria: a clinical and pathological study of nine subjects in six families. Am J Med 1968; 45: 7-25.
6. a ed.). St. Louis: CV Mosby, 1972; 224-281.
7. Schimke RN, McKusik VA, Huang T, Pollack AD. Homocystinuria: studies of 20 families with 38 affected members. JAMA 1965; 193: 711-720.
8. McCully KS. Homocysteine theory of arteriosclerosis. Development and current status. En: Gotto AM Jr, Paoletti R, editores. Atherosclerosis reviews (Vol. 11). Nueva York: Raven Press, 1983; 157-246.
9. Cloppath P, Smith VC, McCully KS. Grow promotion by homocysteic acid. Science 1976; 192: 372-374.
10. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1.909-1.916.
11. Ratnoff OD. Activation of haegman factor by L-homocysteine. Science 1968; 162: 1.007-1.009.
12. Graeber JL, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-493.
13. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuris: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1.400-1.406.
14. Harker LA, Ross R, Schter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
15. Harker LA, Slichter SJ, Scott CR, Ross R Homocysteinernia: vascular injury and arterial trhombosis. N Engl J Med 1974; 291: 537-543.
16. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
17. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
18. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1.906-1.914.
19. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C et al. Coexistence of heredidary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996; 334: 763-768.
20. Franken DG, Vreugdenhil A, Boers GHJ, Verrips A, Bloom HJ, Novakova IRO. Familial cerebrovascular accidents due to concomitant hyperhomocysteinemia and protein C deficiency type 1. Stroke 1993; 24: 1.599-1.600.
21. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877-881.
22. Genest JJ Jr, McNamara JR, Upson B, Salem DN, Ordobas JM, Schaefer EJ et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11: 1.129-1.136.
23. Dudman NPB, Wilcken DEL, Wang J, Lyinch JF, Macey D. Lundberg P. Disorders methionine/homocysteine metabolism in premature vascular disease. Its ocurrence. cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1.253-1.260.
24. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994; 14: 465-470.
25. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. En: Francis RBF. editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. Nueva York: Marcel Dekker, 1992: 183-236.
26. Brattström L, Lindgren A. Hyperhomocysteinemia as a risk factor for stroke. Neurol Res 1992; 14: 81-84.
27. Von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schönfeld R et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardivascular risk factor in men. Arterioscler Thromb 1994; 14: 460-464.
28. Ubbink JB, Vermaak HWJ, Bennett JM, Becker PJ, Van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527-534.
29. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, Pat de Garmo ANP. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
30. Brattström L, Lindgren A. Hyperhomocysteinemia as a risk factor for stroke. Neurol Res 1992; 14: 81-84.
31. Brattström L, Israelson B, Norrving B, Bergovist D, Thorne J, Hultberg B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease-effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51-60.
32. Brattström L, Israelsson B, Hultberg B. Plasma homocysteine and metionine tolerance in early-onset vascular disease. Haemostasis 1989; 19(Supl 1) 35-44.
33. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1.049-1.057.
34. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T et al. Prevalence of hyperhomocystein(e)mia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1.180-1.188.
35. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983; 32: 363-370.
36. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B et al. Hyperhomocysteinemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22: 214-221.
37. Brattström L, Israelsson B, Jeppsson JO, Hultberg B. Folic acid -an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-221.
38. Ubbink JB, Vermaak WJH, Van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1.927-1.933.
39. 12 an folate deficiency. Eur J Haematol 1990; 45: 143-149.
40. Joosten E, Pelemans W, Devos P, Lesaffre E, Goossens W, Criel A et al. Cobalamin absorption and serum homocysteine and methylmatonic acid in elderly subjets with low serum cobalamin. Eur J Haematol 1993; 51: 25-30.
41. Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Genatr Soc 1992; 40: 1.197-1.204.
42. Allen RH, Stabler SP, Savage DG, Lindenbaum J, Diagnosis of cobalamin deficiency, I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematology 1990; 34: 90-98.
43. Fenton AW, Rosenberg LE. Inherited disorders of cobalamin transport and metabolism. En: Scriver CR, Beaudet AL, Sly WS, Valle D, editores. The metabolic and molecular bases of inherited disease. Nueva York: McGraw-Hill Inc., 1995; 3.129-3.149.
44. Rosenblatt DS. Inherited disorders of folate transport and metabolism. En: Scriver CR, Beaudet AL, Sly WS, Valle D, editores. The metabolic and molecular bases of inherited disease, Nueva York: McGraw-Hill Inc., 1995: 3.111-3.128.
45. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM, Finkelstein JD, Bloom HJ, Thomas CMG et al. Maternal hyperhomocysteinemia: a risk factor neural-tube defects? Metabolism 1994; 43: 1.475-1.480.
46. Mills JL, Mcpartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345: 149-151.
47. Wouters MG, Boers GH, Bloom HJ, Trijbels FJ, Thomas CM, Borm GF et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993; 60: 820-825.
48. Steegers-Theunissen RPM, Boers GHJ, Bloom HJ, Trijbels FJM, Eskes TKAB. Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio placentae. N Engl J Med 1992; 339: 1.122-1.123.
49. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-237.
50. Mudd SH, Poole JR. Labile methyl balances for normal humans on varios dietary regimens. Metabolism 1975; 24: 721-735.
51. Mudd SH, Ebert MH, Schriver CR. Labile methyl group balances in the human the role of sarcosine. Metabolism 1980; 29: 707-720.
52. Wiley VC, Dudman NPB, Wilcken DEL. Interrelations between plasma free and protein-bound homocysteine and cysteine in homocystinuria. Metabolism 1988; 37: 191-195.
53. 6. J Nutr 1984; 114: 103-111.
54. Refsum H, Heiland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-628.
55. Gupta VJ, Wilcken DEL. The detection of cysteine-homocysteine mixed disulphide in plasma of normal fasting man. Eur J Clin Invest 1978; 8: 205-207.
56. Córdoba PA, Cirera S, Carrascosa C, Arcelus R, Castellvi A, Rodes M et al. Thermolabile genotype of methylenetetrahydrofolate reductase (MTHFR) and hyperhomocysteinemia in patients with nonhemorrhagic cerebro-vascular disease. The Society for Inborn Errors of Metabolism (SSIEM). Cardiff 34th Annual Symposium. 10th-13th September. J Inherited Metabolic Disease 1996; 19 (Supl 1): 23.
57. Israelsson B, Brattström L, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71: 227-233.
58. Brattström L, Tengborn L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostatis 1991; 21: 51-57.
59. Boers GHJ, Fowler B, Smals AGH, Trijbels FJM, Leermakers AL, Kleijer WJ et al. Improved identification of heterozygotes for homocystinuria due to cystathionine-synthase deficiency by the combination of methionine loading and enzyme determination in cultures fibroblasts. Hum Genet 1985; 69: 164-169.
60. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocystenemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1.149-1.155.
61. a ed.). Vol 1. Nueva York: McGraw-Hill, 1989; 693-734.
62. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase Am J Hum Genet 1988; 43: 414-421.
63. 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism 1988; 37: 175-178.
64. Lindenbaum J, Healton EB, Savage DC, Brust JC, Garrett TJ, Podell ER et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318: 1.720-1.728.
65. Allen RH, Stabler SP, Savage DG, Lindenbaum J, Diagnosis of cobalamin deficiency, I. Usefulness of serum methylmalonic acid and total homocysteine concentratios. Am J Hematol 1990; 34: 90-98.
66. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatographymass spectrometry. J Clin Invest 1988; 81: 466-474.
67. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosemberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2.693-2.698.
68. Murphy-Chutorian DR, Wexman MP, Grieco AJ. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985; 6: 725-730.
69. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice; levels in coronary artery disease. Coronary Artery Disease 1990; 1: 215-220.
70. Genest JJ, McNamara DN, Salem JR, Wilson PWF, Scaefer EJ, Malinow MR. Plasma homocysst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16: 1.114-1.119.
71. Williams RR, Malinow MR, Hunt SC. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Ccron Artery Dis 1990; 1: 681-685.
72. Murphy-Chutorian D, Alderman EL. The case that hyperhomocysteinemia is a risk factor for coronary artery disease. Am J Cardiol 1994; 73: 705-707.
73. Brattström L, Hardebo JE, Hultberg BL. Moderate homocystinemia-a posible risk factor arteriosclerotic cerebrovascular disease. Stroke 1984; 15: 1.012-1.016.
74. Mereau-Richard C, Muller JP, Faivre E, Ardouin P, Rousseaux J, Total plasma homocysteine determination in subjects with premature cerebral vascular disease. Clin Chem 1991; 37: 126.
75. Taylor LM, Defrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13: 128-136.
76. 12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-948.
77. Kang S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocysteine. A possible risk factor for coronary artery disease. J Clin Invest 1986; 77: 1.482-1.486.
78. Ueland PM, Refsum H. Plasma homocysteine a risk factor for vascular disease: plasma levels in healt, disease, and drug therapy J Lab Clin Med 1989; 114: 473-501.
79. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1.395-1.398.
80. Araki A, Sako Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containig amino acids in patients with cerebral infaction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-146.
81. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.
82. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation 1993; 87: 1.107-1.113.
83. Verhoef P, Hennekens CH, Malonow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1.924-1.930.
84. Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
85. Cordoba A, Castellvi A, Rodés M, Arboix A, Iranzo AS, Piles Marti JL et al. Incidencia de hiperhomocisteinemia en pacientes con accidente vascular precoz. VIII congreso Nacional de la Sociedad Espan̄ola de Arteriosclerosis. Clin Invest Arterioscler 1995; 7 (Supl 1): 50.
86. Laghi PF, Frigerio C, Di Perri T. Plasma homocysteine in ischemic stroke. Stroke 1995; 26: 2.374-2.375.
87. Aronson DC, Onkenhout W, Raben AMTJ, Oudenhoven FIJ. Impaired homocysteine metabolism: a risk factor in young adults with atherosclerotic arterial occlusive disease of the leg. Br J Surg 1994; 81: 1.114-1.118.
88. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inemla: an independent risk for intermittent claudication. J Intern Med 1992; 231: 273-279.
89. Selhlub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
90. Bergmark C, Manssor MA, Swedenborg J, De Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50: effect of smoking and extent of disease. Eur J Vasc Surg 1993; 7: 391-396.
91. Wilcken DEL, Wilcken B. The pathogenesis of coronary arteria disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1.079-1.082.
92. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N, Thermolabile methylene tetrahydrofolate reductase: an inherited risk factor coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
93. Kang SS, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988; 37: 611-613.
94. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Shinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of isquemic heart disease in the japanese population. Atherosclerosis 1996; 121: 293-294.
95. Wu LL, Wu J, Hunt SC, James BC, Vicent GM, Williams RR et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994; 40: 552-561.
96. Hopkinns PN, Wu LL, Wu J, Hunt SC, James BC, Vicent GM et al. Higher plasma homocyst(e)ine and icreased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 1.314-1.320.
97. Robinson K, Mayer EL, Miller DP, Green R, Van Lente F, Gupta A et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2.825-2.830.
98. Den Heijer M, Koster T, Blom HJ. Bos GM, Briet E, Reistma PH et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
99. Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
100. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thrombosis 1994; 14: 1.080-1.083.
101. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 1.321-1.323.
102. Burke G, Robinson K, Refsum H, Stuart B, Drumm J, Graham I. Intrauterine growth retardation, perinatal death and maternal homocysteine levels. N Engl J Med 1992; 326: 69-70.
103. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults Arteriosclerosis 1989; 9 (Supl 1): 19-32.
104. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
105. Jocelyn PC Biochemistry of the SH group: the ocurrence, chemical properties, metabolism and biological funtion of thiols and disulphides. Nueva York: Academic Press, Inc., 1972: 84-115.
106. Kannel WB, Sytkowski PA. Atherosclerosis risk factors Pharmacol Ther 1991; 32: 207-235.
107. Sparrow CP, Oszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res 1993; 34: 1.219-1.228.
108. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing aminoacids in Superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10.098-10 103.
109. Hemecke JW, Rosen H, Chait A. Iron an copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984; 74: 1.890-1.894.
110. Córdoba A, Sánchez JL, Rodés M, Acevedo S, Bayen E, Castellvi A et al. Susceptibilidad a la oxidación de las LDL y HDL de pacientes con homocistinuria. VIII congreso Nacional de la Sociedad Espanola de Arteriosclerosis. Clin Invest Arterioscler 1995; 7 (Supl 1): 50.
111. Córdoba PA, Sánchez QJL. González SF, Ordóñez LLJ, Blanco VF. Susceptibility to oxidation of plasma low and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996; 74: 771-776.
112. Blom HJ, Engelen DPE, Boers GHJ, Stadhouders AM, Sengers RCA, De Abreu R et al. Lipid peroxidation in homocysteinemia. J Inher Metab Dis 1992; 15; 419-422.
113. Blom HJ, Kleiveld HA, Boers GHJ, Demacker PNM, Hak-Lemmers HLM, Tepoele-Pothoff MTWB et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25; 149-154.
114. Scanu AM, Pfaffinger D, Fless GM, Makino K, Eisenbart J, Hinman J. Attenuation of immunologic reactivity of lipoprotein (a) by thiols and cysteine-containig compounds. Arterioscler Thromb 1992; 2: 424-429.
115. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10.193-10.197.
116. Wang J, Dudman NPB, Wilcken DEL, Lynch JF. Homocysteine catabolism: levels os 3 enzymes in cultured human vascular endothelium and their relevance to vascular disease. Aterosclerosis 1992; 97: 97-106.
117. Stakebaum G, Harlan JM. Endothelial cell injury due to copper-catalized hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1.370-1.376.
118. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond) 1993; 362: 801-809.
119. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1.177-1.209.
120. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and atherosclerosis in baboons Circ Res 1983; 53: 731-739.
121. Tsai JCH, Perrella MA, Yoshizumi M, Hsieh CHM, Haber E, Schlegel R et al Promotion of vascular smoth muscle cell growth by homocysteine. A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6.369-6.373.
122. Staal FJT, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kB and transcription of human inmunodeficiency virus. Proc Natl Acad Sci USA 1990; 87: 9.943-9.947.
123. Tsukahara T, Ishiura S, Sugita H. Regulation of prolyl endopeptidase activity by the intracellular redox-state. J Bioi Chem 1990; 265: 21.448-21.453.
124. Hentze MW, Rouault TA, Harford JB, Klausner RD. Oxidation-reduction and the molecular mechanism of the regulatory RNA-protein interaction. Science 1989; 244: 357-359.
125. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
126. Giannini MJ, Coleman M, Inerfield I. Antithrombin activity in homocystinuria. Lancet 1975; 1: 1.094.
127. Palareti G, Salardi S, Piazzi S, Piazzi S, Leggnani C, Poggi M et al. Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific theraphy. J Pediatr 1986; 109: 1.001-1.006.
128. Palareti G, Coccheri S Lowered antitrombina III activity and other clotting changes in homocystinuria. Effects of a pyridoxine-folate regimen. Haemostasis 1989; 19 (Supl 1): 24-28.
129. Maruyana I, Fukuda R, Kazama M, Abe T, Yoshida V, Igata A. A case of homocystinuria with low antithrombin activity. Act Haematol Jpn 1977; 40: 267-271.
130. Beresford CH. Antithrombin III deficiency. Blood Rev 1988; 2: 239-250.
131. Beresford CH, Owen MC. Antithrombin III. Int J Biochem 1990; 22: 121-128.
132. Schienle HW, Seitz R, Rohner I, Lerch L, Krumpholz B, Krauss G et al. Coagulation factors and markers of activation of coagulation in homocystinuria: a study in two siblings. Blood Coagul Fibrinolysis 1994; 5: 873-878.
133. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1.381-1.386
134. Ewadh MJA, Tudball W, Roese FA. Homocysteine uptake by human umbilical vein endothelial cells in culture. Biochim Biophys Acta 1990; 1.054: 263-266.
135. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2.873-2.879.
136. Hayashi T, Honda G, Suzuki K, An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin espression in human umbilical vein endothelial cells. Blood 1992; 79: 2.930-2.936.
137. Schienle HW, Seitz R, Nawroth P, Rohner I, Lerch L, Krumpholz B et al. Thrombomodulin and ristocetincofactor in homocystinuria: a study in two siblings. Thromb Res 1995; 77: 79-86.
138. Cereveny TJ, Fass DN, Mann KG. Synthesis of coagulation factor V by cultured aortic endothelium. Blood 1984; 63: 1.467-1.474.
139. Rodgers GM, Kane WH, Pitas RE. Formation of factor Va by atherosclerotic rabbit aorta mediate factor Xa-catalized prothrombin activation. J Clin Invest 1988; 81: 1.911-1.919.
140. Rodgers GM, Shuman MA. Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci USA 1983; 80: 7.001-7.005.
141. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 1987; 327: 524-526.
142. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endotheliumderived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9.265-9.269.
143. Stamler JS, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF et al. N-acetyl-cysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65: 789-795.
144. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T et al. S-nitrosylation of protein with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992; 89: 444-448.
145. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1.327-1.333.
146. Van Maldergem L, Capel, Boeynaems JM. Increased prostacyclin biosynthesis in a patient with homocystinuria. Eur J Pediatr 1990; 149: 666-667.
147. Boers GHJ, Smals AGH, Drayer JIM, Trijbels FJM, Leermakers AI, Kloppenberg PW. Pyridoxine treatment does not prevent homocystinemia after methionine loading in adult homocystinuria patients. Metab Clin Exp 1983; 32: 390-397.
148. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency. Possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.
149. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346: 85-86.
150. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci 1981; 61: 743-749.
151. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocystememia. J Vase Surg 1994; 20: 933-940.
152. Holme E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child 1989; 64: 1.061-1.064.
153. Chanarin I. Adverse effects of increased dietary folate. Relation to measures to reduce the incidence of neural tube defects. Clin Invest Med 1994; 17: 244-252.
154. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993; 103: 149-157.
155. Boers GHJ. Carriership for homocystinuria in juvenile vascular disease. Haemostasis 1989; 19 (Supl 1): 29-34.
156. Winklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serun lipoprotein(a) levels. Atherosclerosis 1996; 119: 99-106.